Heart failure & cardiomyopathiesCohort study
The cardiac microcurrent (C-MIC) II follow-up study: safety and efficacy results 12 months after deactivation of cardiac microcurrent therapy
- Prospective follow-up study
- single-group
Authors' conclusion
Among patients previously treated with C-MIC device, improvements in LVEF, 6MWD, NYHA class and KCCQ-OSS were sustained, with a favorable safety profile 12 months post-deactivation.
Study context
- Population
- Patients with non-ischemic heart failure with reduced ejection fraction (HFrEF) previously treated with 6 months of cardiac microcurrent (C-MIC) therapy, after device deactivationof 32 eligible
- Participants
- 31 patients
- Outcome
- Safety: all-cause, CV and device-related mortality and hospitalizations, and adverse events (AEs)
- Follow-up
- 12 months post-deactivation
Main finding
As reported in the abstract
Safety
Hospitalized
3 (10%)
Died
1 (3%)
Device-related hospitalizations or deaths
0
Device-related AE (resolved completely)
1
Observational data: associations, not effects.
Secondary outcomes
| Outcome | change (%) (95% CI) | P value | |
|---|---|---|---|
| LVEF change · 18 months — 18 months vs 6 months | −0.1 (−2-2) | P = 0.87 | |
| −3−2−10123Difference, % (linear scale) |
| Outcome | change (95% CI) | P value | |
|---|---|---|---|
| KCCQ-OSS change · 18 months — 18 months vs 6 months | −2 (−8-4) | P = 0.49 | |
| −10−505Difference (linear scale) |
| Outcome | change (m) (95% CI) | P value | |
|---|---|---|---|
| 6MWD change · 18 months — 18 months vs 6 months | −31 (−56- −7) | P = 0.013 | |
| −100−50050Difference, m (linear scale) |
| Outcome | Estimate | P value |
|---|---|---|
| LVEF change · 18 months — 18 months vs Pre-implantation | change +6 % (95% CI 5–8) | P < 0.0001 |
| KCCQ-OSS change · 18 months — 18 months vs Pre-implantation | change +43 points (95% CI 36–49) | P < 0.0001 |
| 6MWD change · 18 months — 18 months vs Pre-implantation | change +150 m (95% CI 109–191) | P < 0.0001 |
New York Heart Association (NYHA) class · 18 months
- ≥1-class improvement sustained
- 77%
Device reactivation · 18 months
- Required device reactivation
- 3 (10%)
Original publication
The C-MIC II follow-up study: safety and efficacy results 12 months after deactivation of cardiac microcurrent therapy. Eur J Heart Fail. Published 26 August 2026. doi:10.1093/ejhf/xuag274
Summarised from the published abstract; every number is checked against it